Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 34454548)

  • 1. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; McIntosh J; Li Y; Che Y; Jessen KA; Lannutti BJ; Wang M
    J Hematol Oncol; 2021 Aug; 14(1):132. PubMed ID: 34454548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
    Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
    Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
    J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma.
    Jiang VC; Liu Y; Jordan A; Leeming A; McIntosh J; Huang S; Zhang R; Cai Q; Chen Z; Li Y; Che Y; Nie L; Karlsson I; Mårtensson L; Kovacek M; Teige I; Frendéus B; Wang M
    J Hematol Oncol; 2022 Apr; 15(1):42. PubMed ID: 35410313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease.
    Tarockoff M; Gonzalez T; Ivanov S; Sandoval-Sus J
    Curr Oncol Rep; 2022 Oct; 24(10):1313-1326. PubMed ID: 35639332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?
    Beitinjaneh A; Kaufman A; Wang Y; Jain P; Srour SA; Wang M
    Curr Treat Options Oncol; 2022 Nov; 23(11):1614-1625. PubMed ID: 36227407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma.
    Romancik JT; Gerber DG; Zhuang T; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):557-565. PubMed ID: 35123927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner.
    Munoz JL; Wang Y; Jain P; Wang M
    Curr Oncol Rep; 2022 Oct; 24(10):1299-1311. PubMed ID: 35596920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies in mantle cell lymphoma.
    Hanel W; Epperla N
    J Hematol Oncol; 2020 Jun; 13(1):79. PubMed ID: 32552760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.
    Hudecek M; Lupo-Stanghellini MT; Kosasih PL; Sommermeyer D; Jensen MC; Rader C; Riddell SR
    Clin Cancer Res; 2013 Jun; 19(12):3153-64. PubMed ID: 23620405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma.
    Jiang VC; Hao D; Jain P; Li Y; Cai Q; Yao Y; Nie L; Liu Y; Jin J; Wang W; Lee HH; Che Y; Dai E; Han G; Wang R; Rai K; Futreal A; Flowers C; Wang L; Wang M
    Mol Cancer; 2022 Sep; 21(1):185. PubMed ID: 36163179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
    Deshpande A; Wang Y; Munoz J; Jain P
    Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.
    Wang ML; Barrientos JC; Furman RR; Mei M; Barr PM; Choi MY; de Vos S; Kallam A; Patel K; Kipps TJ; Rule S; Flanders K; Jessen KA; Ren H; Riebling PC; Graham P; King L; Thurston AW; Sun M; Schmidt EM; Lannutti BJ; Johnson DM; Miller LL; Spurgeon SE
    NEJM Evid; 2022 Jan; 1(1):EVIDoa2100001. PubMed ID: 38319241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients With Mantle Cell Lymphoma Who Progress on BTK Inhibitors.
    Nayak RK; Gerber D; Zhang C; Cohen JB
    Clin Lymphoma Myeloma Leuk; 2023 Dec; 23(12):861-865. PubMed ID: 37661513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR T-Cell therapy for the management of mantle cell lymphoma.
    Huang Z; Chavda VP; Bezbaruah R; Dhamne H; Yang DH; Zhao HB
    Mol Cancer; 2023 Mar; 22(1):67. PubMed ID: 37004047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
    Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
    Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma.
    Li P; Dong N; Zeng Y; Liu J; Tang X; Wang J; Zhang W; Ye S; Zhou L; Chang AH; Liang A
    Front Med; 2020 Dec; 14(6):811-815. PubMed ID: 32651937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions.
    Bond DA; Martin P; Maddocks KJ
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33799484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.